Rhodiola Rosea vs Selank
Two anxiety/stress compounds from very different traditions — a synthetic Russian anxiolytic peptide claimed to match benzodiazepines, against an adaptogenic root with a genuine, if modest, placebo-controlled trial record.
Short answer
Rhodiola rosea and Selank both have human clinical data, so the deciding factor is what you want them for. Rhodiola rosea suits someone focused on stress, fatigue and focus, while Selank is aimed at anxiety and focus. Selank matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized.
Rhodiola Rosea
Several placebo-controlled RCTs show a short-term benefit for stress-related fatigue and mental performance — but trials are small/lower-quality and systematic reviews call it promising, not proven.
Full Rhodiola Rosea evidence reviewSelank
A GABA-modulating anxiolytic that matched benzodiazepines in small Russian trials; the mechanism is credible but the evidence base is thin and single-country.
Full Selank evidence reviewRhodiola Rosea vs Selank: head to head
- FDA status / approved use
Rhodiola Rosea
Herbal adaptogen supplement; not a treatment for clinical depression or any diagnosed conditionSelank
Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide- Marketed for
Rhodiola Rosea
Stress, fatigue, focusSelank
Anxiety, focus- Outcome areas
Rhodiola Rosea
Mood / anxiety / stress; Cognitive function / memory; Mitochondrial / cellular energySelank
Mood / anxiety / stress; Cognitive function / memory- Evidence grade
Rhodiola Rosea
Clinical dataSelank
Clinical data- How it works
Rhodiola Rosea
Adaptogen claimed to help the body resist stress; active markers rosavins and salidrosideSelank
Modulates the GABA system without acting as a benzodiazepine- Route and dosing
Rhodiola Rosea
Oral standardized extract, commonly 200 to 400 mg/daySelank
Nasal spray (intranasal)- Headline human result
Rhodiola Rosea
Greater fatigue reduction than placebo after 28 days of standardized SHR-5 extract in an RCT of adults with stress-related fatigueSelank
Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized- Strongest evidence
Rhodiola Rosea
Olsson RCT, Planta Med 2009Rhodiola Rosea evidence reviewPubMed 19016404Selank
Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395- Key safety signal
Rhodiola Rosea
Mild dizziness, dry mouth or jitteriness; may interact with antidepressants, stimulants, blood-pressure or blood-sugar drugsSelank
No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern- How it is obtained
Rhodiola Rosea
Over the counter as a dietary supplementSelank
Sold gray-market as a research chemical; no approved or legitimately compounded human product
| Rhodiola Rosea | Selank | |
|---|---|---|
| FDA status / approved use | Herbal adaptogen supplement; not a treatment for clinical depression or any diagnosed condition | Reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide |
| Marketed for | Stress, fatigue, focus | Anxiety, focus |
| Outcome areas | Mood / anxiety / stress; Cognitive function / memory; Mitochondrial / cellular energy | Mood / anxiety / stress; Cognitive function / memory |
| Evidence grade | Clinical data | Clinical data |
| How it works | Adaptogen claimed to help the body resist stress; active markers rosavins and salidroside | Modulates the GABA system without acting as a benzodiazepine |
| Route and dosing | Oral standardized extract, commonly 200 to 400 mg/day | Nasal spray (intranasal) |
| Headline human result | Greater fatigue reduction than placebo after 28 days of standardized SHR-5 extract in an RCT of adults with stress-related fatigue | Matched benzodiazepines on anxiety in small Russian trials (n=62 vs medazepam), none described as randomized |
| Strongest evidence | Olsson RCT, Planta Med 2009Rhodiola Rosea evidence reviewPubMed 19016404 | Medvedev, Korsakov J 2015Selank evidence reviewPubMed 26356395 |
| Key safety signal | Mild dizziness, dry mouth or jitteriness; may interact with antidepressants, stimulants, blood-pressure or blood-sugar drugs | No large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern |
| How it is obtained | Over the counter as a dietary supplement | Sold gray-market as a research chemical; no approved or legitimately compounded human product |
marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
- Clinical data:
- Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Our verdict
Selank's evidence is a GABA-modulating mechanism that matched benzodiazepines in small Russian trials — credible mechanism, but the evidence base is thin and effectively single-country. Rhodiola has a broader, if lower-quality, body of placebo-controlled trials specifically for stress-related fatigue and mental performance, with systematic reviews calling it promising rather than proven.
Rhodiola Rosea fits if
You want the more accessible, more internationally studied option for everyday stress and fatigue.
Selank fits if
You're specifically interested in the peptide/nasal-spray route and the GABA-modulation mechanism, accepting the evidence is single-country.
Rhodiola Rosea vs Selank: common questions
- Is either Rhodiola rosea or Selank FDA-approved?
- No. Rhodiola rosea is an herbal adaptogen supplement; not a treatment for clinical depression or any diagnosed condition. Selank is reportedly past Phase III in Russia; not FDA-approved; sold in the US as a research peptide.
- Which has stronger human evidence, Rhodiola rosea or Selank?
- Neither clearly. Both have human clinical data. The key source for Rhodiola rosea is Olsson RCT, Planta Med 2009; for Selank, it is Medvedev, Korsakov J 2015.
- What are the main safety concerns with Rhodiola rosea and Selank?
- For Rhodiola rosea, watch for mild dizziness, dry mouth or jitteriness; may interact with antidepressants, stimulants, blood-pressure or blood-sugar drugs. Selank has no large human safety database; lab work showed anti-clotting activity, a theoretical bleeding concern.
Key studies behind each
Rhodiola Rosea
- Olsson EM, von Schéele B, Panossian AG. (2009). A randomised, double-blind, placebo-controlled, parallel-group study of the standardised extract SHR-5 of the roots of Rhodiola rosea in the treatment of subjects with stress-related fatigue. Planta Med. PubMed 19016404
- Darbinyan V, Kteyan A, Panossian A, Gabrielian E, Wikman G, Wagner H. (2000). Rhodiola rosea in stress induced fatigue--a double blind cross-over study of a standardized extract SHR-5 with a repeated low-dose regimen on the mental performance of healthy physicians during night duty. Phytomedicine. PubMed 11081987
- Spasov AA, Wikman GK, Mandrikov VB, Mironova IA, Neumoin VV. (2000). A double-blind, placebo-controlled pilot study of the stimulating and adaptogenic effect of Rhodiola rosea SHR-5 extract on the fatigue of students caused by stress during an examination period with a repeated low-dose regimen. Phytomedicine. PubMed 10839209
- Mao JJ, Xie SX, Zee J, Soeller I, Li QS, Rockwell K, Amsterdam JD. (2015). Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. PubMed 25837277
Selank
- Vyunova TV, Andreeva L, Shevchenko K, et al. (2018). Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. PubMed 30255741
- Volkova A, Shadrina M, Kolomin T, et al. (2016). Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. PubMed 26924987
- Zozulya AA, Kost NV, Sokolov OYu, et al. (2001). The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bull Exp Biol Med. PubMed 11550013
- Doyno CR, White CM. (2021). Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank. J Clin Pharmacol. PubMed 34396551
The full evidence reviews
- Rhodiola rosea: what the evidence actually shows for fatigue, stress, and focus
The adaptogen with the most focused signal — decent short-term RCT data for stress-related fatigue and mental performance under load, a modest mood effect, and systematic reviews that call it promising but not yet proven.
Updated August 2026
- Selank: a non-benzodiazepine anxiolytic peptide, lightly tested
A tuftsin-analog heptapeptide that modulates GABA without being a benzodiazepine — and matched benzodiazepines in small Russian trials. The mechanism is credible; the evidence base is thin.
Updated August 2026
Where to get it
Where to get peptide therapy
Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Selank availability before ordering.
Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.
- Oak LongevityPartner
Low-cost sermorelin within a broader longevity stack
- HealthRXPartner
Compounded sermorelin within a broad longevity and weight-care menu
Bodybuilding Health+PartnerSermorelin from Bodybuilding.com's telehealth program
Provider reviews we publish: Nova MDNu Image MedicalNucificNucore HealthNuform HealthNäky